SPOTLIGHT: BioMarin, Genzyme restructure pact

BioMarin, Genzyme restructure pact
BioMarin and Genzyme have restructured their pact for Aldurazyme, an enzyme replacement treatment for the rare disease MPS 1. The companies say that the revision will reduce management time and provide stronger incentives for each company. Release

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.